FDA Grants Full Approval to Iptacopan for IgA Nephropathy

The U.S. Food and Drug Administration (FDA) granted full approval to iptacopan (Fabhalta) on Friday, March 22, 2024, for the treatment of adults diagnosed with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. This marks a significant milestone as iptacopan is the first complement inhibitor to receive full FDA approval for this specific kidney condition. The drug's efficacy in slowing the decline of kidney function in IgAN patients was demonstrated through clinical trials, leading to this regulatory decision by the FDA.

Novartis, the pharmaceutical company behind Fabhalta, announced the approval, highlighting its potential to alter the course of IgAN, a chronic autoimmune kidney disease characterized by the buildup of IgA antibodies in the kidneys. This accumulation can lead to inflammation and damage, ultimately impairing kidney function. The full approval follows previous designations and reviews by the FDA, underscoring the drug's established safety and effectiveness profile for the targeted patient population.

Iptacopan works by inhibiting the complement system, a part of the immune system that can become overactive in IgAN and contribute to kidney damage. By targeting this pathway, the drug aims to reduce the inflammatory processes that drive disease progression. The approval is based on comprehensive data from clinical studies that showed a statistically significant benefit in preserving kidney function over time compared to placebo or standard care. This development offers a new therapeutic option for patients who previously had limited treatment choices for managing their IgAN and its long-term consequences.